Down -8.24% in 4 Weeks, Here's Why Regeneron (REGN) Looks Ripe for a TurnaroundZacks Investment Research • 04/29/24
Countdown to Regeneron (REGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPSZacks Investment Research • 04/29/24
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal DiseasesGlobeNewsWire • 04/29/24
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCOGlobeNewsWire • 04/24/24
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)GlobeNewsWire • 04/22/24
The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of InvestorsBusiness Wire • 04/17/24
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 04/13/24
Regeneron (REGN) Accused of Fraudulent Practices Related to EyleaZacks Investment Research • 04/12/24
Are Regeneron's Legal Troubles — And Six-Week Slide — A Buying Opportunity?Investors Business Daily • 04/11/24
Regeneron Stock Under Microscope After DOJ Price Reporting Complaint—Key Levels to WatchInvestopedia • 04/11/24